All News

A pooled analysis compared survival among patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy and either targeted therapy or immunotherapy regimens utilizing checkpoint inhibitors.

Research suggested oncologists may recommend specific timeframes in which cystectomy should be performed to avoid unnecessary mortality due to delays.

The study evaluated lurbinectedin (Zepzelca) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine for adult patients with small cell lung cancer whose disease progressed following 1 prior platinum-containing line of therapy.

Researchers sought to better understand the impact of treatment on intimate relationships for patients with bladder cancer.

Janssen submitted a biologics license application to the FDA seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

The director of the new Women’s Lung Cancer Program at Mount Sinai spoke about the gaps in lung cancer research for women and what she hopes this new program will offer women moving forward.

The guidance is intended to inform gastroenterologists of how to assess lesions for endoscopic features associated with cancer, discuss how these factors guide endoscopic management, and to outline the factors that frame whether to advise surgery after a malignant polyp has been endoscopically resected.

The clinical trial indicated that supplementation with vitamin D reduced the incidence of advanced cancer in the overall study population of adults without a diagnosis of cancer at baseline, with the strongest risk reduction seen in individuals with normal weight.

The agency granted fast track designation to irinotecan liposome injection for patients with small cell lung cancer who progressed following a first-line platinum-based regimen.

The FDA granted accelerated approval to pralsetinib to treat with advanced or metastatic RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer.

The agency approved the first PSMA-targeted PET imaging drug to treat men with prostate cancer.

The agent’s new drug application will be reviewed under the FDA’s Real Time Oncology Review pilot program and under Project Orbis.

A recent study found that rural non-Hispanic whites and blacks have experienced increased HCC case incidence rates, while urban areas have seen the rate decline since 2009.

According to researchers, these immuno-oncologic differences may aid in developing a genomically adaptive approach to treating prostate cancer in this patient population.

A study published in JAMA Surgery found that low quantity and low quality of muscle can predict poor outcomes after colon cancer surgery.

The FDA granted accelerated approval to naxitamab-gqgk (Danyelza) in combination with GM-CSF for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.

This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.

Low EC-pY397-FAK expression levels were found to be associated with chemotherapy sensitivity and improved 5-year relapse-free survival after systemic therapy in patients with neoadjuvant-treated locally advanced breast cancer.

This trial is the first randomized trial of men with recurring prostate cancer to show that treatment based on advanced molecular imaging can improve disease-free survival rates.

Women with onset of breast cancer over age 65 typically do not qualify for genetic testing, however this study demonstrated that frequency of pathogenic variants and risk of breast cancer is not negligible in this patient population.

These results emphasize the importance of defining patterns of variance in early-onset CRC survival in order to understand the impact of community health behaviors on early-onset CRC outcomes.

A phase 2 trial found that the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.

The phase 3 BOSTON study suggested that a once-per-week combination regimen of selinexor (Xpovio), bortezomib (Velcade), and dexamethasone (Ozurdex) is an effective treatment option for patients with multiple myeloma who have received 1 to 3 previous lines of therapy.

Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.

This study found that state-level lung cancer screening rates were not aligned with disease burden, with the exception of Kentucky, which has supported comprehensive efforts to implement lung cancer screening.

According to the researchers, the high-quality evidence observed thus far supports the endorsement of this scoring system as a new staging system for prostate cancer.

These results suggested that adolescent and young adult patients treated for acute myeloid leukemia have a high risk of developing long-term health complications.

A study presented at ASTRO suggested that response-based consolidation involved-field radiation therapy appears to be a safe and effective standard of care for a cohort of pediatric patients with high-risk classical Hodgkin lymphoma.

Though researchers found that Black patients with early-stage non-small cell lung cancer are now more likely to receive the most effective treatment compared to a decade ago, the disparity for this patient population persists.

“This might raise the potential of being able to detect disease recurrence much earlier than current clinical practice,” said Thomas Weiland, MD.